Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration

Published:2020-08-01 Issue:8 Volume:138 Page:835
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Jackson Timothy L.¹²,Soare Cristina²,Petrarca Caroline¹,Simpson Andrew¹²,Neffendorf James E.¹²,Petrarca Robert¹²,Muldrew Alyson³,Peto Tunde⁴,Chakravarthy Usha³,Membrey Luke⁵,Haynes Richard⁶,Costen Mark⁷,Steel David⁸⁹,Desai Riti²,

Affiliation:

1. Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom

2. Department of Ophthalmology, King’s College Hospital, London, United Kingdom

3. NetwORC UK, Central Angiographic Reading Center, Queen’s University of Belfast, Belfast, United Kingdom

4. Reading Center, Moorfields Eye Hospital, London, United Kingdom

5. Department of Ophthalmology, Maidstone Hospital, Maidstone, United Kingdom

6. Department of Ophthalmology, Bristol Eye Hospital, Bristol, United Kingdom

7. Department of Ophthalmology, Hull and East Yorkshire Eye Hospital, Hull, United Kingdom

8. Vitreoretinal Unit, Sunderland Eye Infirmary, Sunderland, United Kingdom

9. Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2768081/jamaophthalmology_jackson_2020_oi_200048_1597179663.87583.pdf

Reference25 articles.

1. The estimated prevalence and incidence of late stage age related macular degeneration in the UK.;Owen;Br J Ophthalmol,2012

2. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.;Wong;Lancet Glob Health,2014

3. Ranibizumab for neovascular age-related macular degeneration.;Rosenfeld;N Engl J Med,2006

4. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.;Schmidt-Erfurth;Ophthalmology,2014

5. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.;Holz;Br J Ophthalmol,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience of using stereotactic radiotherapy combined with anti-vascular endothelial growth factor to treat neovascular AMD;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-03-06

2. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid;Ophthalmology;2022-09

3. Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial;British Journal of Ophthalmology;2022-02-25

4. Epimakuläre Brachytherapie reduziert nicht die Anzahl an Ranibizumab-Injektionen;Augenheilkunde up2date;2021-02

5. Epimakuläre Brachytherapie reduziert nicht die Anzahl an Ranibizumab-Injektionen;Klinische Monatsblätter für Augenheilkunde;2020-11